Announced Fri, 10 Apr · 19:49 IST
Lupin launches Dapagliflozin Tablets in US after FDA approval
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.1%1-day move
₹2333.80
prior close
₹2316.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1+0.4+0.3-0.3+0.1-0.4-0.5-0.2-0.9+0.6+4.8-4.8-2.7+6.6
Up moveDown movePending
AI summary
Lupin has launched Dapagliflozin Tablets (5 mg and 10 mg) in the United States after the U.S. FDA approved its Abbreviated New Drug Application (ANDA). The tablets are bioequivalent to AstraZeneca's Farxiga, a leading diabetes drug. This expands Lupin's anti-diabetic generic portfolio in the U.S. market and adds a new revenue stream in the world's largest pharmaceutical market.
Likely market impact
Positive: strengthens Lupin's U.S. diabetes franchise with a new generic launch, but Farxiga faces heavy generic competition which may limit pricing power.